124 related articles for article (PubMed ID: 6343127)
1. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study.
Blackwell RE; Bradley EL; Kline LB; Duvall ER; Vitek JJ; DeVane GW; Chang RJ
Fertil Steril; 1983 Jun; 39(6):744-8. PubMed ID: 6343127
[TBL] [Abstract][Full Text] [Related]
2. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia.
Kletzky OA; Borenstein R; Mileikowsky GN
Am J Obstet Gynecol; 1986 Feb; 154(2):431-5. PubMed ID: 3080892
[TBL] [Abstract][Full Text] [Related]
3. Metergoline and bromocriptine in the management of tumoral and idiopathic hyperprolactinemia.
Falsetti L; Roggia A; Loda G; Turla R; Scagliola T; Schimberni M; Pontiroli AE
Horm Metab Res; 1983 Aug; 15(8):380-4. PubMed ID: 6618428
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemic primary amenorrhea: case report with successful prolactin-lowering treatment and review of the literature.
Farrari C; Telloli P; Rampini P; Caldara R
Gynecol Obstet Invest; 1980; 11(6):317-26. PubMed ID: 6785158
[TBL] [Abstract][Full Text] [Related]
5. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.
Horowitz BL; Hamilton DJ; Sommers CJ; Bryan RN; Boyd AE
AJNR Am J Neuroradiol; 1983; 4(3):415-7. PubMed ID: 6410759
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of hyperprolactinemic conditions with bromoergocryptine].
Sas M; Godó G; Morvay J
Zentralbl Gynakol; 1978; 100(22):1501-7. PubMed ID: 570784
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
8. The effect of dopamine agonist therapy on large functionless pituitary tumours.
Grossman A; Ross R; Charlesworth M; Adams CB; Wass JA; Doniach I; Besser GM
Clin Endocrinol (Oxf); 1985 May; 22(5):679-86. PubMed ID: 4028461
[TBL] [Abstract][Full Text] [Related]
9. Discordant responses of prolactinoma to two different dopamine agonists.
Ahmed SR; Shalet SM
Clin Endocrinol (Oxf); 1986 Apr; 24(4):421-6. PubMed ID: 3742834
[TBL] [Abstract][Full Text] [Related]
10. The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
Bergh T; Nillius SJ; Wide L
Acta Eur Fertil; 1984; 15(6):421-4. PubMed ID: 6536135
[TBL] [Abstract][Full Text] [Related]
11. Restoration of the prolactin response to sulpiride by metergoline administration in hyperprolactinemic patients.
Ferrari C; Travaglini P; Caldara R; Moriondo P; Mattei A; Crosignani PG; Faglia G
Neuroendocrinology; 1979; 29(5):338-45. PubMed ID: 503288
[No Abstract] [Full Text] [Related]
12. The pathophysiology of hyperprolactinemic states and the role of newer ergot compounds in their treatment.
Frantz AG; Kleinberg DL
Fed Proc; 1978 Jun; 37(8):2192-7. PubMed ID: 26606
[TBL] [Abstract][Full Text] [Related]
13. Ovarian refractoriness to gonadotropins in cases of inappropriate lactation: restoration of ovarian function with bromocryptine.
Mroueh AM; Siler-Khodr TM
J Clin Endocrinol Metab; 1976 Dec; 43(6):1398-401. PubMed ID: 1036743
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.
Grossman A; Bouloux PM; Loneragan R; Rees LH; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1985 May; 22(5):611-6. PubMed ID: 4028459
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride.
Crosignani PG; Ferrari C; Liuzzi A; Benco R; Mattei A; Rampini P; Dellabonzana D; Scarduelli C; Spelta B
Fertil Steril; 1982 Jan; 37(1):61-7. PubMed ID: 7199483
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts SW; Quik RF
J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
[TBL] [Abstract][Full Text] [Related]
17. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
Franks S; Horrocks PM; Lynch SS; Butt WR; London DR
Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1177-9. PubMed ID: 6404378
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and treatment of hyperprolactinaemia in women of childbearing age.
Marek J; Zivný J; Srámková J; Kucera E; Kobilková J
Acta Univ Palacki Olomuc Fac Med; 1981; 101():110-7. PubMed ID: 6242681
[No Abstract] [Full Text] [Related]
20. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography.
Johnston DG; Hall K; Kendall-Taylor P; Patrick D; Watson M; Cook DB
Lancet; 1984 Jul; 2(8396):187-92. PubMed ID: 6146751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
